Zevra Therapeutics (ZVRA) EBIAT (2016 - 2025)
Zevra Therapeutics (ZVRA) has disclosed EBIAT for 10 consecutive years, with $12.2 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT rose 134.04% year-over-year to $12.2 million, compared with a TTM value of $83.2 million through Dec 2025, up 178.85%, and an annual FY2025 reading of $83.2 million, up 178.88% over the prior year.
- EBIAT was $12.2 million for Q4 2025 at Zevra Therapeutics, up from -$544000.0 in the prior quarter.
- Across five years, EBIAT topped out at $74.7 million in Q2 2025 and bottomed at -$35.7 million in Q4 2024.
- Average EBIAT over 5 years is -$5.3 million, with a median of -$9.0 million recorded in 2022.
- The sharpest move saw EBIAT surged 622.12% in 2021, then plummeted 674.39% in 2024.
- Year by year, EBIAT stood at -$2.7 million in 2021, then plummeted by 233.74% to -$9.0 million in 2022, then plummeted by 120.51% to -$19.9 million in 2023, then plummeted by 79.67% to -$35.7 million in 2024, then surged by 134.04% to $12.2 million in 2025.
- Business Quant data shows EBIAT for ZVRA at $12.2 million in Q4 2025, -$544000.0 in Q3 2025, and $74.7 million in Q2 2025.